ArticleMolecular cancer2022

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.

Mareike Berlak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.